Jennifer Grossman is a Rheumatology/Immunology physician affiliated with University of California, Los Angeles. OpenAlex indexes 182 publications with 12,442 citations (h-index 29).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 Medical Plaza
#365,530,420,120
Los Angeles, CA 90095
Telephone
310-206-3244Registry record last updated 24 Jun 2010.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20241 payment
- Aurinia Pharma U.S., Inc.Program year20231 payment
- Novartis Pharmaceuticals CorporationProgram year20224 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
19.3%TNF inhibitor10.1%Enbrel Sureclick43%Enbrel27%Humira(Cf) Pen16%Cimzia (2 Pack)15%Part D<11 patientsFolate Analog Metabolic Inhibitor5.8%Methotrexate100%Part D≥16 patients+ 2 more classes in this area
Antiparasitic
17.6%Antimalarial17.6%Hydroxychloroquine Sulfate100%Part D≥49 patientsMetabolism & gastrointestinal
16.2%Corticosteroid13.5%Prednisone100%Part D≥31 patientsProton pump inhibitor1.5%Pantoprazole Sodium100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2000–2001 per NIH RePORTER. The latest:
- Consumer oriented interactive osteoarthritis fact sheet
University of California Los Angeles
FY2001$159,355P60AR036834 - Consumer oriented interactive osteoarthritis fact sheet
University of California Los Angeles
FY2000$159,355P60AR036834
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis
Arthritis & Rheumatology
2025 - Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production
Annals of the Rheumatic Diseases
2016
Similar KOLs
Other experts from the same institution or the same specialty.
Gregg Fonarow, MD
University of California, Los Angeles
Dennis Slamon, MD
University of California, Los Angeles
Tomas Ganz, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”